Edition:
United States

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

138.97USD
8 Dec 2017
Change (% chg)

$4.14 (+3.07%)
Prev Close
$134.83
Open
$134.94
Day's High
$139.12
Day's Low
$134.09
Volume
188,739
Avg. Vol
154,455
52-wk High
$163.69
52-wk Low
$99.53

Chart for

About

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $8,331.32
Shares Outstanding(Mil.): 59.95
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.13 15.67
EPS (TTM): -- -- --
ROI: -- 15.10 34.62
ROE: -- 16.59 16.00

BRIEF-Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer

* JAZZ PHARMACEUTICALS ANNOUNCES APPOINTMENT OF DANIEL SWISHER AS PRESIDENT AND CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Dec 04 2017

BRIEF-Jazz Pharmaceuticals posts Q3 EPS of $1.03

* Jazz pharmaceuticals announces third quarter 2017 financial results

Nov 07 2017

BRIEF-Jazz Pharma submits Vyxeo Marketing Authorization Application to European Medicines Agency

* Jazz Pharmaceuticals submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for treatment of certain types of high-risk acute myeloid leukemia Source text for Eikon: Further company coverage:

Nov 03 2017

BRIEF-Jazz Pharma announces $500 mln offering of 1.50 pct exchangeable senior notes due 2024

* Jazz Pharmaceuticals Plc - ‍offering of $500 million aggregate principal amount of 1.50% exchangeable senior notes due 2024​

Aug 18 2017

BRIEF-Jazz Pharmac announces offering of $500 mln of exchangeable senior notes

* Jazz Pharmaceuticals announces offering of $500 million of exchangeable senior notes due 2024

Aug 17 2017

BRIEF-Jazz Pharmaceuticals Q2 adjusted earnings per share $2.56

* Jazz Pharmaceuticals announces second quarter 2017 financial results

Aug 08 2017

BRIEF-Jazz Pharmaceuticals announces FDA approval of Vyxeos

* Jazz Pharmaceuticals announces FDA approval of Vyxeos™ (Daunorubicin and Cytarabine) liposome for injection for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

Aug 03 2017

BRIEF-Jazz Pharmaceuticals and XL-protein GmbH enter into license agreement

* Jazz Pharmaceuticals and XL-protein GmbH enter into a license agreement on PASylation technology to develop long-acting asparaginase product candidates

Jul 26 2017

BRIEF-Jazz Pharmaceuticals says on June 28, its unit entered into pharmacy master services agreement with Express Scripts specialty distribution services

* Jazz Pharmaceuticals says on June 28, its unit entered into a pharmacy master services agreement with express scripts specialty distribution services

Jul 03 2017

Earnings vs. Estimates